Peptide

Sermorelin

Sermorelin acetate

A 29-amino-acid fragment of GHRH that stimulates the pituitary to release growth hormone. FDA-approved in the 1990s for pediatric growth-hormone deficiency, later withdrawn from the US market as a branded drug but still legally compounded.

Editor approved

Summary Can sermorelin slow aging or improve health? Show / hide ↓

Sermorelin is a 29-part fragment of a natural hormone signal that tells the pituitary gland, a small gland in the brain, to release growth hormone. It was approved in 1997 in the United States for children with growth-hormone deficiency, but the branded product was later withdrawn and compounded versions are still prescribed. Old, small adult studies found modest increases in IGF-1, a blood marker linked to growth hormone, and small changes in body composition. No randomized controlled trial, meaning a study that compares treatments fairly by chance, has shown that sermorelin extends life or prevents disease in older adults. Clinics often combine it with other peptides, but the published research does not support these combination treatments.

What this means for you: Sermorelin has a real medical history, but evidence for healthy aging in adults is weak. Do not assume that raising IGF-1 will extend life or improve long-term health.

weak evidence

Research snapshot FDA approved for pediatric GH deficiency (rarely prescribed). Off-label use in anti-aging clinics.

Updated 2026-08-11

Sermorelin is a synthetic growth hormone-releasing hormone fragment that was FDA-approved for pediatric growth hormone deficiency but discontinued for commercial reasons. It is now used off-label in anti-aging clinics. Limited human data exists for adult body composition or longevity outcomes.

Evidence tierTier 3, Mixed human evidence, mechanism plausible

Typical doseAdult protocols in anti-aging clinics: 200-500 mcg subcutaneous injection at bedtime, 5-6 nights per week. Compounded formulations vary. Pediatric dosing is weight-based and used only under endocrinology care.

SafetyInjection-site reactions, flushing, and occasional headache are the most reported effects. Long-term effects of chronically elevating GH pulses in adults are not well studied. Raising IGF-1 above age-appropriate levels may not be benign given the association between higher IGF-1 and some cancers.

Categoryprescription peptide

Last verified2026-08-05

Sermorelin sits in a very different category from the research-chemical peptides that dominate biohacker forums. It is a legally prescribed drug with a real history: approved in 1997 for pediatric GH deficiency, prescribed off-label for adult 'age-related GH decline' by anti-aging clinics for two decades, and still routinely compounded and prescribed in 2026.

Mechanically, sermorelin acts on the pituitary. It binds the GHRH receptor and triggers a pulse of growth hormone. Unlike direct GH injection, sermorelin preserves the normal negative feedback loop — somatostatin can still shut down the pituitary — which is why proponents argue it is safer than exogenous GH. The trade-off is that GH release is modest and short-lived, and adults with truly age-related low IGF-1 do not always respond as robustly as pediatric patients.

Evidence in adults is old. Most controlled studies date to the 1990s and early 2000s and show modest IGF-1 increases, small body-composition changes, and no proven longevity endpoint. There is no RCT showing that raising IGF-1 in aging adults extends lifespan or reduces disease risk. In fact, some Mendelian-randomization and observational data suggest lower IGF-1 in mid-life may associate with longer life.

Anti-aging clinics still prescribe sermorelin heavily, often in combination with ipamorelin or CJC-1295 for supposed synergy. The peer-reviewed literature does not support the combination protocols. If you are on sermorelin under a legitimate prescription, know that you are treating a symptom (low IGF-1) whose relationship to healthy aging is genuinely unclear.

Related in the encyclopedia

Further reading